| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cardiol Therapeutics Inc.$1.01
+0.02 (+1.81%)
D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
147.67 M
EPS
-0.28
P/E Ratio
-
Value Trade
921.69 K
-1.49 %
Week
-19.02 %
1 Month
26.92 %
3 Month
34.69 %
6 Month
-48.84 %
5 Year
-64.72 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
361.63 K
52 Week Range
0.88 - 1.71
% held by Insiders
3.05 %
% held by Institutions
24.96 %
Enterprise Value
127.86 M
Total Shares
115.24 M
Short %
1.98 %
Float Shares
111.86 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardiol Therapeutics Inc.
179Total events
9Upcoming
23Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 9
Event history 170
May 19, 2026
◆Oral PresentationPresentation
Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
May 11, 2026
●Quarterly UpdateCorporate
Released Q1 2026 financial results for three months ended March 31, 2026
May 7, 2026
▲PublicationCardiolRxPresentation
Phase II MAvERIC results accepted for publication in Journal of the American Heart Association
recurrent pericarditissource ↗
May 7, 2026
▲Enrollment MilestoneCardiolRxTrial
Phase III MAVERIC trial surpassed 75% enrollment
recurrent pericarditissource ↗
Apr 28, 2026
▲Enrollment UpdateCardiolRxTrial
Enrollment surpassed 50% threshold in early January and has now reached 75%
recurrent pericarditissource ↗
Apr 14, 2026
◆Oral PresentationPresentation
Live interview with Barchart discussing MAVERIC Phase III trial and ARCHER results
Q2 2026
◆Enrollment CompleteCardiolRxTrial
Target recruitment anticipated by end of Q2 2026, with potential extension into Q3
recurrent pericarditissource ↗
Mar 4, 2026
Feb 10, 2026
▲Full ResultsCardiolRxClinical Data
ARCHER Phase II study results published in ESC Heart Failure
acute myocarditissource ↗
Feb 2026
▲Full ResultsCardiolRxClinical Data
Full ARCHER study results published in ESC Heart Failure
acute myocarditissource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $15M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankCardiol Therapeutics Inc. faces pipeline headwinds (27/100), with $186M risk-adjusted pipeline value, led by CardiolRx in Acute Myocarditis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CardiolRx Small molecule | Recurrent Pericarditis | Phase 3 | NCT05494788 | 68% | $186M | COMPLETED | 137 | - | - | Sep 6, 2024 | MODERATE_RISK | Oct 20, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CardiolRx Orphan | recurrent pericarditis | Phase 2 | 2026-05-07 | rapid and sustained reductions in pericarditis pain and inflammation, substantial reduction in pericarditis episodes per year Read More | Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx may represent a paradigm shift in the treatment of patients with recu Read More | |
CardiolRx Orphan | recurrent pericarditis | Phase 2 | 2026-05-07 | rapid and sustained reductions in pericarditis pain and inflammation, substantial reduction in pericarditis episodes per year Read More | Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx may represent a paradigm shift in the treatment of patients with recu Read More | |
CardiolRx Orphan | recurrent pericarditis | Phase 2 | 2026-05-07 | rapid and sustained reductions in pericarditis pain and inflammation, substantial reduction in pericarditis episodes per year Read More | Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx may represent a paradigm shift in the treatment of patients with recu Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRDL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRDL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRDL▲ +1.8%today
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. The company is advancing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA. This engagement underscores Cardiol's commitment to addressing significant health challenges in cardiology.
Read more →CRDL▲ +1.8%today
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. The company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate, CardiolRx, currently in pivotal Phase III trials for recurrent pericarditis. The event will take place in Boston, MA.
Read more →CRDLCardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics held its Annual General Meeting on June 24, 2026, where shareholders voted in favor of all proposed management resolutions. Key outcomes included the election of several directors and the appointment of BDO Canada LLP as auditors. The company continues to focus on developing therapies for heart disease, including its lead candidate, CardiolRx.
Read more →CRDLCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Cardiol Therapeutics Inc. will host its virtual Annual General Meeting (AGM) on June 24, 2026, at 4:30 p.m. EDT. The meeting will be accessible via live webcast. The company is focused on developing therapies for heart disease, including its lead candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA.
Read more →CRDLCARDIOL THERAPEUTICS INC. 602-2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual general meeting (the " Meeting ") of the hol
Cardiol Therapeutics Inc. has announced the schedule for its annual general meeting of shareholders, set to take place on June 24, 2026. Shareholders must return their proxies or votes 48 hours before the meeting. The company is utilizing an online format to facilitate participation and intends to distribute materials through electronic posting, reflecting a move towards sustainable practices. The record date for shareholder eligibility is set for May 7, 2026.
Read more →CRDLCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, which has received FDA Orphan Drug Designation. The ongoing MAVERIC trial is pivotal for the treatment of recurrent pericarditis.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2026 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
Cardiol Therapeutics Inc. reported its condensed interim consolidated financial statements for the three months ending March 31, 2026. The company registered a net loss of 10.82 million CAD, which reflects a significant increase compared to the same period in the previous year. Despite an increase in total assets and cash reserves, total liabilities also rose. The financial outlook indicates challenges as operating expenses remain high, thereby exerting pressure on profitability.
Read more →CRDLCardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics announced that results from its Phase II MAvERIC study on CardiolRx™ for recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association. The findings indicate significant reductions in pain and inflammation, supporting the ongoing Phase III MAVERIC trial, which has exceeded 75% enrollment. The publication underscores the potential of CardiolRx™ as a non-immunosuppressive treatment option.
Read more →CRDLCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx may represent a paradigm shift in the treatment of patients with recu
Cardiol Therapeutics has announced that results from its Phase II MAvERIC study on CardiolRx have been accepted for publication in the Journal of the American Heart Association. The findings suggest that CardiolRx can significantly reduce pain and inflammation in patients suffering from recurrent pericarditis. The positive clinical data supports the ongoing Phase III MAVERIC trial, which has achieved over 75% enrollment. The publication underscores the potential for CardiolRx as a non-immunosuppressive treatment option in managing this condition, addressing a significant unmet medical need.
Read more →CRDLWhy the Most Common Form of Heart Failure Is Also the Hardest to Treat
Heart failure with preserved ejection fraction (HFpEF) is becoming the dominant form of heart failure, yet treatment options remain inadequate. This condition is characterized by a stiff heart muscle that cannot relax properly, leading to severe symptoms and high mortality rates. Researchers are now focusing on underlying mechanisms like inflammation to develop more effective therapies tailored to HFpEF.
Read more →CRDLCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics has expanded its MAVERIC Phase III trial network in the U.S., responding to increased interest from major clinical centers. Patient enrollment has surged to 75%, with a target of 110 participants expected by the end of Q2 2026. The trial builds on positive Phase II results and aims to support a New Drug Application with the FDA.
Read more →CRDLCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northweste
Cardiol Therapeutics announced the expansion of its MAVERIC Phase III trial in the U.S., planning to activate up to seven additional clinical centers. Patient enrollment has reached 75%, with expectations to complete recruitment by the end of Q2 2026. The trial, which evaluates CardiolRx for preventing recurrence of pericarditis, reflects significant interest from leading academic institutions. The trial's design was verified with the FDA, ensuring regulatory alignment for the ongoing pivotal study.
Read more →CRDLHeart Failure Is Getting Worse. Understanding Why Is the First Step.
Heart failure is increasingly prevalent, affecting over 64 million globally, with projections indicating further growth. In the U.S., the number of cases is expected to rise from 6.7 million to 11.4 million by 2050. The condition's complexity, particularly heart failure with preserved ejection fraction (HFpEF), presents significant treatment challenges, as many patients do not receive recommended therapies. This highlights a critical need for new approaches in cardiovascular medicine.
Read more →CRDL▲ +7.9%on this news
Understanding Clinical Trials: What Each Stage Means and Why Phase III Matters
The article explains the importance of clinical trial phases, particularly Phase III, which is critical for proving a therapy's efficacy and safety. It outlines the progression from Phase I, focusing on safety, to Phase II, which tests for activity, and finally to Phase III, where definitive evidence is gathered. The significance of Phase III trials in cardiovascular medicine is emphasized, especially in demonstrating meaningful improvements for patients.
Read more →CRDLCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Cardiol Therapeutics Inc. announced that CEO David Elsley will participate in a live interview discussing the MAVERIC Phase III trial of CardiolRx™ for recurrent pericarditis and the recently published ARCHER trial results for acute myocarditis. The interview will take place on April 14, 2026, at 12:00 PM EDT. The company is also developing CRD-38 for heart failure.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Toronto, ON
Cardiol Therapeutics announced a live interview featuring CEO David Elsley, focusing on the MAVERIC Phase III trial and the recently published ARCHER trial results. The MAVERIC trial is pivotal for evaluating CardiolRx in recurrent pericarditis, while the ARCHER trial studies its efficacy in acute myocarditis. Furthermore, the company is developing CRD-38, a novel treatment for inflammatory heart disease including heart failure. The interview underscores the company's commitment to advancing therapies for heart diseases.
Read more →CRDLCardiol Therapeutics Announces Year-End 2025 Update on Operations
Cardiol Therapeutics provided a year-end update for 2025, highlighting the initiation of the Phase III MAVERIC trial for recurrent pericarditis and positive Phase II ARCHER results in acute myocarditis. The company advanced its CRD-38 program towards Phase I development and secured a U.S. patent for its therapies. Financially, Cardiol raised $31 million, ensuring funding through 2027.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Year-End 2025 Update on Operations Initiated pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and surpassed 50% patient enrollment, with full
Cardiol Therapeutics has provided a comprehensive update on its operations as of year-end 2025, highlighting the initiation of the pivotal Phase III MAVERIC trial for CardiolRx in recurrent pericarditis, where patient enrollment is over half complete. The company also reported positive outcomes from its Phase II ARCHER study, demonstrating significant benefits in left ventricular mass reduction for patients with acute myocarditis. Additionally, the development of CRD-38 is advancing towards Phase I clinical trials, aimed at addressing heart failure and inflammatory heart diseases. A U.S. patent allowance has been granted, safeguarding the company's therapeutic candidates until late 2040.
Read more →CRDLFrom Symptom Management to Disease Modification: A Shift in Cardiology
The article discusses a significant shift in cardiology from symptom management to disease modification. This transition focuses on addressing the underlying biological processes driving heart diseases, particularly inflammation. By moving beyond merely stabilizing patients, the goal is to alter the disease's long-term trajectory and improve patient outcomes. Cardiol Therapeutics emphasizes the importance of this approach in developing therapies that promote durable recovery.
Read more →CRDLWhy Inflammation Is Becoming One of the Most Important Targets in Cardiology
The article discusses the increasing recognition of inflammation as a primary factor in cardiovascular diseases, shifting the focus from merely managing symptoms to addressing inflammation directly. This change is expected to lead to more effective treatments and improved long-term outcomes for patients. Cardiol Therapeutics is at the forefront of this approach, aiming to reshape treatment paradigms in inflammatory heart conditions.
Read more →CRDLCardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Cardiol Therapeutics is set to present at the TD Cowen 46th Annual Health Care Conference. This event provides a platform for the company to showcase its developments and engage with potential investors. The conference is a significant opportunity for Cardiol to highlight its strategic initiatives and future directions.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference Toronto, ON
Cardiol Therapeutics Inc. (NASDAQ: CRDL) will present at the TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 4, 2026. The company focuses on developing innovative therapies for heart disease, with its lead candidate, CardiolRx, targeting conditions like recurrent pericarditis and myocarditis. Notably, CardiolRx has received Orphan Drug Designation for the treatment of recurrent pericarditis, emphasizing its significance in addressing unmet medical needs in heart health.
Read more →CRDLWhat Is Pericarditis (And Why Better Treatments Matter)
Pericarditis is an inflammatory condition affecting the heart's protective membrane, leading to painful symptoms and potential recurrences. Current treatments focus on symptom management but have limitations, prompting the need for better therapies. Cardiol Therapeutics is conducting the MAVERIC trial to evaluate a targeted approach that may modify the disease and improve patient outcomes.
Read more →CRDLARCHER Results Published: Strengthening the Scientific Foundation for Cardiol’s Pivotal Phase III MAVERIC Trial
Cardiol Therapeutics announced the publication of results from its Phase II ARCHER study, which evaluated CardiolRx™ in patients with acute myocarditis. The study demonstrated a significant reduction in left ventricular mass and improved safety profile, indicating CardiolRx™ effectively reduces inflammation in cardiac tissue. These findings bolster confidence in the upcoming Phase III MAVERIC trial targeting recurrent pericarditis.
Read more →CRDLCardiol Therapeutics’ ARCHER Phase II Study Results Published in ESC Heart Failure
Cardiol Therapeutics has published results from its Phase II ARCHER study in ESC Heart Failure, showing that CardiolRx significantly reduces left ventricular mass in patients with acute myocarditis. The study involved 109 patients and demonstrated favorable trends in myocardial inflammation markers. The findings support ongoing Phase III trials for recurrent pericarditis.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Toronto, ON
Cardiol Therapeutics announced the publication of results from its Phase II ARCHER study in the journal ESC Heart Failure. The study evaluated the efficacy of CardiolRx, showing a significant reduction in left ventricular mass and favorable trends in myocardial inflammation among patients with acute myocarditis. Additionally, the safety profile was favorable; the findings may enhance the confidence in the ongoing pivotal Phase III MAVERIC trial for recurrent pericarditis. The publication signals progress in advancing therapies for inflammatory heart diseases.
Read more →CRDLUnderstanding Myocarditis: How Inflammation Can Weaken the Heart
Myocarditis is an inflammation of the heart muscle that can arise from viral infections or autoimmune conditions. It can lead to serious complications and is often underdiagnosed. Cardiol Therapeutics is investigating CardiolRx™ in a Phase II trial, showing potential to reduce inflammation and support heart recovery. The ongoing research aims to address the underlying causes of myocarditis.
Read more →CRDLCardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Cardiol Therapeutics has successfully closed a bought deal financing, raising gross proceeds of $14.85 million. The financing included the full exercise of the over-allotment option, which strengthens the company's financial position. This capital will support Cardiol's ongoing projects and initiatives.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Toronto, ON
Cardiol Therapeutics Inc. has successfully closed a bought deal financing, raising gross proceeds of $14.85 million by issuing 11,423,078 Units. This includes the full exercise of the over-allotment option by the underwriter, Canaccord Genuity Corp. Each Unit consists of one common share and one-half of a warrant, with net proceeds earmarked for research, clinical development, and general expenses. The financing was conducted under applicable exemptions in Canada, allowing for significant flexibility in capital raising without extensive regulatory hurdles.
Read more →CRDLExecution Version
Cardiol Therapeutics Inc. has entered into an underwriting agreement with Canaccord Genuity Corp. to issue 11,423,078 units at a price of $1.30 each, aiming for gross proceeds of approximately $14.85 million. Each unit includes one common share and half a common share purchase warrant. The company is utilizing a bought deal structure, which reflects strong market interest. The transaction is scheduled to close on January 23, 2026, pending the fulfillment of conditions outlined in the agreement.
Read more →CRDL▲ +10.1%on this news
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Cardiol Therapeutics Inc. has announced a bought deal financing agreement to raise $13.5 million through the sale of 10,384,616 units at $1.30 each. The financing aims to support the company's research and clinical development initiatives, particularly for its lead drug candidate, CardiolRx™, which targets inflammatory heart diseases. The offering is set to close around January 23, 2026, pending necessary approvals.
Read more →CRDL▲ +10.1%on this newsshared move
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Cardiol Therapeutics Inc. has announced a bought deal financing that will generate gross proceeds of $13.5 million. This financing is expected to bolster the company's financial position and support its growth strategies. The successful deal indicates strong investor interest in Cardiol's future prospects.
Read more →CRDL▲ +10.1%on this newsshared move
Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 - Name and Address of Company Cardiol Therapeutics Inc. (" Cardiol " or the " Company ") 2265 Upper Middle Road East, Suite 602 Oakville, Ontario, L6H
Cardiol Therapeutics Inc. announced a bought deal private placement offering, raising $13.5 million through the sale of 10,384,616 units at $1.30 each. The underwriter, Canaccord Genuity Corp., has an option to purchase an additional 10% of the units sold. The proceeds will be allocated to advance the company's research, clinical programs, and general expenses. The closing of the offering is expected around January 23, 2026, pending necessary approvals.
Read more →CRDL▲ +10.1%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Toronto, ON
Cardiol Therapeutics Inc. has announced a bought deal financing to raise gross proceeds of $13.5 million through the sale of 10,384,616 units at $1.30 each. The financing will support the company's research, clinical development programs, and general expenses. The deal allows for an additional 10% of units to be sold, contributing up to $1.35 million more. The offering is scheduled to close on or about January 23, 2026, contingent on receiving necessary approvals.
Read more →CRDLCardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics has successfully achieved a 50% patient enrollment milestone in its pivotal Phase III MAVERIC trial, which is focused on treating recurrent pericarditis. This milestone marks a significant step forward in the trial's progress and highlights the company's commitment to addressing this serious health condition. The MAVERIC trial aims to evaluate the efficacy and safety of Cardiol's treatment in affected patients.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Clinical trial infrastructure fully operational in the U.S. with m
Cardiol Therapeutics has achieved a key milestone in its Phase III MAVERIC trial for the treatment of recurrent pericarditis, surpassing 50% patient enrollment. The trial is being conducted at more than 15 leading cardiovascular centers across the U.S., with additional sites in Europe and Canada. The company anticipates full enrollment by Q2 2026 and highlights the strong demand for effective treatments in this area. CardiolRx is positioned as a novel oral therapy aimed at reducing serious disease recurrence among patients.
Read more →CRDL▼ -9.5%on this news
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx™ Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
The Phase II ARCHER trial demonstrated that CardiolRx™ significantly reduces left ventricular mass and improves cardiac MRI measures in patients with acute myocarditis. The results provide clinical evidence supporting CardiolRx™'s potential to mitigate inflammation-driven heart damage, reinforcing its development for broader inflammatory cardiac conditions. The findings were presented at a major cardiology conference.
Read more →CRDL▼ -9.5%on this newsshared move
Filed by newsfilecorp.com New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions Phase II AR
Cardiol Therapeutics has released positive data from its Phase II ARCHER trial, demonstrating that CardiolRx significantly improves heart structure in patients suffering from acute myocarditis. Key findings included a marked reduction in left ventricular mass and improvements in cardiac MRI measures, highlighting the treatment's effectiveness in promoting heart recovery. These results not only strengthen the case for CardiolRx but also support its application for other inflammatory cardiac conditions, positioning it as a promising therapeutic advancement in heart disease management.
Read more →CRDLCardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Cardiol Therapeutics has received a Notice of Allowance for a U.S. patent covering CardiolRx™ and CRD-38, which will protect their use in treating various cardiac disorders until 2040. This patent enhances Cardiol's intellectual property portfolio and supports their clinical programs for heart diseases characterized by inflammation and fibrosis. The company anticipates presenting data from their ARCHER trial at an upcoming conference.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of
Cardiol Therapeutics has announced receiving a Notice of Allowance for a U.S. patent that will broadly protect its drugs CardiolRx and CRD-38 for various cardiac disorders until late 2040. This significant development not only strengthens Cardiol’s intellectual property strategy in the U.S., but it also comes alongside their ongoing clinical studies on severe heart conditions, including myocarditis and pericarditis. The company plans to present data from its ARCHER trial at the upcoming European Society of Cardiology Annual Meeting, reinforcing its role in addressing major unmet medical needs in heart disease treatment.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consoli
Cardiol Therapeutics Inc. has released its interim financial statements for the third quarter and nine months ending September 30, 2025. The company reported a net loss of approximately $26.6 million for the nine-month period, despite holding cash reserves of about $11.6 million. The total equity significantly decreased to approximately $9.56 million compared to the previous year. Notably, the operating expenses remain elevated, raising concerns about financial sustainability moving forward.
Read more →CRDLCardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Cardiol Therapeutics announced that results from its Phase II ARCHER trial will be presented at the European Society of Cardiology meeting. The trial demonstrated significant improvements in cardiac structure in patients with acute myocarditis. The presentation will be delivered by Dr. Leslie T. Cooper, highlighting the potential of CardiolRx to address inflammatory heart diseases. A webcast conference call is scheduled for December 1, 2025, to discuss these findings.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases The ESC M&PD meeting brings toge
Cardiol Therapeutics announced that results from its Phase II ARCHER trial will be presented at the European Society of Cardiology meeting in Trieste, Italy. The trial showcased significant improvements in patients with acute myocarditis, notably regarding cardiac structure. The company will also discuss these findings in a webcast conference on December 1, 2025. With its innovative anti-inflammatory candidate, CardiolRx, Cardiol aims to impact the treatment landscape for heart disease significantly.
Read more →CRDLForm 45-106F1 Report of Exempt Distribution Item 1 – REPORT TYPE ☒ New report ☐ Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) Item 2– PARTY CERTI
Cardiol Therapeutics Inc. has filed a Form 45-106F1 Report of Exempt Distribution as required by Canadian securities legislation. This report pertains to the distribution of securities and includes personal information of individuals involved. The issuer confirms that all individuals listed have been informed about the report's filing with the securities regulatory authority in their jurisdictions. The personal information collected is intended for the purposes of administering and enforcing local securities legislation.
Read more →CRDL▲ +15.2%on this news
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Cardiol Therapeutics has successfully completed a US$11.4 million financing, which will support its MAVERIC Phase III trial for CardiolRx™ in recurrent pericarditis and the development of its next-generation therapy, CRD-38. The company reported promising results from the ARCHER trial, demonstrating a significant reduction in left ventricular mass, which could have implications for heart failure treatment. This funding extends the company's cash runway into Q3 2027.
Read more →CRDL▲ +15.2%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is full
Cardiol Therapeutics has successfully completed a US$11.4 million financing, ensuring full funding for its MAVERIC Phase III trial of CardiolRx, an orphan drug candidate for recurrent pericarditis. Promising data from the ARCHER trial reveals a significant reduction in left ventricular mass, which could lead to further development and an Orphan Drug Designation for myocarditis. The financing will also support the development of CRD-38, a novel therapy aimed at heart failure, with discussions for partnerships ongoing. This financial boost extends the company's operational runway into Q3 2027, highlighting investor confidence in its pipeline.
Read more →CRDLCardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Cardiol Therapeutics has completed a private placement offering, securing US$11 million to support its clinical trials and the development of its heart failure drug, CRD-38. The funding will allow the company to continue its pivotal Phase III MAVERIC trial and advance discussions with pharmaceutical partners. Recent data from the ARCHER trial shows significant reductions in left ventricular mass, indicating potential benefits for heart failure patients.
Read more →CRDLFiled by newsfilecorp.com Form 51-102F3 Material Change Report ITEM 1 NAME AND ADDRESS OF ISSUER Cardiol Therapeutics Inc. (" Cardiol " or the " Company ") 2265 Upper Middle Road East, Suite 602 Oakville, Ontario, Canada
Cardiol Therapeutics Inc. announced the completion of a private placement offering, raising $11.4 million. Proceeds from the offering will strengthen the company's financial position and support operations into the third quarter of 2027. The funding is particularly significant as it enables continued development of the CRD-38 therapy and the MAVERIC Phase III trial. Additionally, promising results from the ARCHER trial were highlighted as a key factor in their ongoing clinical strategy.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully fu
Cardiol Therapeutics has successfully secured US$11 million in financing, strengthening its position as it progresses through the MAVERIC Phase III pivotal trial for CardiolRx in recurrent pericarditis. The funding is expected to extend the company's cash runway into Q3 2027 and supports ongoing recruitment efforts at several centers in the U.S. Positive findings from the ARCHER trial indicate significant improvements in left ventricular mass associated with CardiolRx. The company is also pursuing the development of its next-generation heart failure therapy, CRD-38.
Read more →CRDL▲ +20.7%on this news
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2025 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated
Cardiol Therapeutics Inc. released its interim consolidated financial statements for the six months ended June 30, 2025, reporting a net loss of $16.64 million, which is an increase from $15.77 million for the same period in 2024. The company's total assets dropped from approximately $31.86 million at the end of 2024 to about $19.94 million. Elevated operational costs and decreasing cash reserves underscore ongoing financial challenges faced by the company in its clinical development efforts, particularly related to its lead drug candidate, CardiolRx.
Read more →CRDLCardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference
Cardiol Therapeutics Inc. will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12, 2025. The company focuses on developing therapies for heart disease, including its lead candidate, CardiolRx™, which is in clinical development. The event will be accessible via a live webcast, with a replay available for 90 days.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference Toronto, ON
Cardiol Therapeutics Inc. (NASDAQ: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston on August 12, 2025. The company is focused on developing therapies for heart disease, particularly through its lead drug candidate, CardiolRx. This involvement in the conference marks a potential opportunity for investor engagement as the company progresses with its clinical studies and trials. Additionally, Cardiol has received FDA authorization for several clinical studies related to heart disease treatments.
Read more →CRDL▼ -20.7%on this newsshared move
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis
Cardiol Therapeutics announced positive topline results from the Phase II ARCHER trial, demonstrating significant improvements in left ventricular extracellular volume (ECV) with CardiolRx™ compared to placebo. The trial showed a notable reduction in ECV and LV mass, supporting further development of CardiolRx™ for acute myocarditis and other cardiac conditions. The results will be presented at an upcoming scientific meeting.
Read more →CRDL▼ -20.7%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV)
Cardiol Therapeutics has announced topline results from the Phase II ARCHER trial of CardiolRx for treating acute myocarditis. The trial demonstrated a notable improvement in left ventricular extracellular volume compared to placebo, with supportive data across various cardiac imaging endpoints. The findings provide a strong case for advancing CardiolRx’s clinical development for cardiomyopathies and related conditions. The results will be shared at an upcoming scientific meeting and submitted for publication.
Read more →CRDL▲ +14.8%on this news
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis
Cardiol Therapeutics has announced the database lock for its Phase II ARCHER trial, which investigates CardiolRx™ for myocardial recovery in acute myocarditis patients. This trial is significant as there are currently no FDA-approved therapies for this condition. Topline results are anticipated within the next two weeks, which may guide further development strategies for heart disease treatments.
Read more →CRDL▲ +14.8%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx in Acute Myocarditis ARCHER is designed to assess the impact of CardiolRx on cardiac magnetic resonance imagin
Cardiol Therapeutics has announced the database lock for the Phase II ARCHER trial, which investigates the effects of CardiolRx on patients with acute myocarditis. This trial is crucial as acute myocarditis currently lacks FDA-approved drug therapies. Topline results from the trial are anticipated within two weeks, which will enable statistical analysis and provide insights into the treatment's efficacy. The trial includes over 100 patients enrolled across multiple countries, aiming to evaluate cardiac function and fibrosis indicators.
Read more →CRDLCardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Cardiol Therapeutics held its Annual General Meeting on May 28, 2025, where shareholders approved all management resolutions, including the election of new directors. Dr. Timothy Garnett was appointed to the Board, bringing over 30 years of pharmaceutical experience. The company is progressing in its Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis and preparing for results from its Phase II ARCHER trial.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders Toronto, ON
Cardiol Therapeutics held its Annual General Meeting on May 28, 2025, where shareholders voted in favor of all proposed resolutions, including the appointment of directors. Notably, Dr. Timothy Garnett joined the Board, bringing extensive drug development experience. The company is currently focused on clinical trials for CardiolRx, targeting conditions like recurrent pericarditis and acute myocarditis. This reflects Cardiol's ongoing commitment to addressing significant heart disease challenges through innovative therapies.
Read more →CRDL▲ +5.5%on this news· ran to +16% by day 1shared move
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Cardiol Therapeutics Inc. will host its virtual Annual General Meeting (AGM) on May 28, 2025, at 4:30 p.m. EDT. The meeting will be accessible via a live audio webcast. The company is focused on developing therapies for heart disease, including its lead candidate, CardiolRx, which has received FDA authorization for clinical studies.
Read more →CRDL▲ +5.5%on this news· ran to +16% by day 1shared move
Filed by newsfilecorp.com Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28 th at 4:30 p.m. EDT Toronto, ON
Cardiol Therapeutics Inc. is set to host its virtual Annual General Meeting (AGM) on May 28, 2025, at 4:30 p.m. EDT. The meeting will be available via live audio webcast and is intended for shareholders to participate and vote. Cardiol is focused on developing therapies for heart disease and has received FDA authorization for its lead drug candidate, CardiolRx. This AGM presents an opportunity for the company to engage stakeholders on its progress and future plans.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2025 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
Cardiol Therapeutics Inc. reported its interim financial results for the three months ending March 31, 2025. The company experienced a net loss of $8,287,653, which was an improvement over the loss of $9,179,632 from the previous year. However, current assets have decreased significantly, and the total deficit has continued to rise, revealing underlying financial challenges for the company. This quarterly performance raises concerns about Cardiol's liquidity and operational sustainability.
Read more →CRDL▲ +6.5%on this news
Cardiol Therapeutics Nominates Dr. Timothy Garnett to its Board of Directors
Cardiol Therapeutics has nominated Dr. Timothy Garnett, a former Chief Medical Officer at Eli Lilly, to its Board of Directors. With over 30 years of experience, Dr. Garnett's expertise in clinical development and regulatory strategy is expected to enhance Cardiol's efforts, particularly as they initiate patient enrollment in their Phase III MAVERIC trial for heart disease. His appointment is seen as a significant milestone for the company.
Read more →CRDL▲ +6.5%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Nominates Dr. Timothy Garnett to its Board of Directors Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto
Cardiol Therapeutics has nominated Dr. Timothy Garnett to its Board of Directors. Dr. Garnett, a former Chief Medical Officer at Eli Lilly, possesses over thirty years of experience in the pharmaceutical industry. His extensive background in clinical development and successful drug launches is anticipated to contribute significantly to Cardiol's objectives, especially with the recent initiation of the Phase III MAVERIC trial for heart disease treatment. The company is focused on developing anti-inflammatory and anti-fibrotic therapies, particularly its lead candidate CardiolRx.
Read more →CRDLCardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics has enrolled its first patient in the pivotal Phase III MAVERIC trial, which aims to evaluate the efficacy of CardiolRx™ in preventing recurrent pericarditis. Following positive Phase II results, the trial is designed to support a New Drug Application with the US FDA. The study will involve approximately 110 patients across multiple sites in the US, Canada, and Europe.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditi
Cardiol Therapeutics has announced the enrollment of the first patient in their pivotal Phase III MAVERIC trial, which aims to evaluate CardiolRx in patients with recurrent pericarditis. This trial follows positive results from the Phase II MAvERIC-Pilot study, suggesting CardiolRx can significantly mitigate pain and inflammation in these patients. The trial is set to involve 110 patients across various clinical sites and aims to gather data to support a New Drug Application with the FDA. CardiolRx has previously been granted Orphan Drug Designation by the FDA for its potential role in treating this condition.
Read more →CRDLCardiol Therapeutics Announces Year-End 2024 Update on Operations
Cardiol Therapeutics provided an operational update for year-end 2024, highlighting positive results from the Phase II MAvERIC-Pilot study for CardiolRx™ in recurrent pericarditis, which supports advancing to Phase III trials. The company also completed enrollment in the ARCHER trial for acute myocarditis, with topline data expected in Q2 2025. Additionally, CardiolRx™ received Orphan Drug Designation from the FDA, enhancing its development prospects.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Year-End 2024 Update on Operations Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with
Cardiol Therapeutics provided a positive year-end operational update for 2024, highlighting encouraging data from the Phase II MAvERIC-Pilot study of CardiolRx for recurrent pericarditis. The company completed patient enrollment in the Phase II ARCHER trial, with topline data expected by Q2 2025. Additionally, CardiolRx received Orphan Drug Designation from the FDA, underlining its commitment to addressing significant heart disease challenges. The company's financial status remains strong, with sufficient cash reserves to fund operations through mid-2026.
Read more →CRDL▼ -5.2%on this news
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Cardiol Therapeutics Inc. will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The company is developing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate, CardiolRx. The FDA has authorized clinical studies for CardiolRx in recurrent pericarditis and acute myocarditis.
Read more →CRDL▼ -5.2%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference Toronto, ON
Cardiol Therapeutics Inc. (NASDAQ: CRDL) will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025. The company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx, is in clinical development for conditions like recurrent pericarditis and acute myocarditis. Cardiol has received FDA approval for clinical trials and holds Orphan Drug Designation for CardiolRx for specific heart diseases.
Read more →CRDL▲ +6.6%on this news
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Cardiol Therapeutics announced the publication of research in the Journal of the American College of Cardiology, supporting its proprietary drug candidate CRD-38 for heart failure. The study indicates that CRD-38, a subcutaneous formulation of cannabidiol, improves cardiac function and reduces key heart failure mechanisms. The findings provide a strong rationale for advancing CRD-38 into clinical development.
Read more →CRDL▲ +6.6%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutane
Cardiol Therapeutics has announced the publication of research in the Journal of the American College of Cardiology which supports the development of its subcutaneous drug candidate CRD-38 for treating heart failure. The study showcases significant improvements in cardiac function and reductions in inflammation and cell death. Collaborating researchers demonstrated that CRD-38 could preserve mitochondrial function in cardiac cells, potentially addressing key issues in heart failure progression. This research is a critical step in advancing CRD-38 through clinical development as Cardiol plans to complete necessary IND-enabling work.
Read more →CRDL▲ +5.3%on this news
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cardiol Therapeutics Inc. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The company focuses on anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate, CardiolRx, in clinical development. The FDA has granted authorization for studies on recurrent pericarditis and acute myocarditis, highlighting its commitment to addressing serious heart conditions.
Read more →CRDL▲ +5.3%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics to Present at Oppenheimer 35 th Annual Healthcare Life Sciences Conference Toronto, ON
Cardiol Therapeutics Inc. announced it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease and has received FDA authorization for clinical studies on their lead candidate, CardiolRx. This presentation is part of their efforts to highlight advancements in treatment options for heart disease, including ongoing clinical trials.
Read more →CRDLCardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics presented positive results from its Phase II MAvERIC-Pilot study at the American Heart Association Scientific Sessions 2024. The study demonstrated significant reductions in pericarditis pain and inflammation, with improvements maintained over 26 weeks. These findings support the advancement of CardiolRx into Phase II/III and Phase III trials aimed at preventing recurrence of pericarditis.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 Marked and rapid reductions in both p
Cardiol Therapeutics presented positive results from its Phase II MAvERIC-Pilot study at the American Heart Association Scientific Sessions 2024. The study demonstrated significant reductions in pericarditis pain and inflammation over 26 weeks, with improvements sustained throughout the trial's duration. The results support the company's plans to advance CardiolRx into later-stage clinical trials aimed at recurrent pericarditis treatment, showcasing the potential of the therapy for patients suffering from this condition.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consoli
Cardiol Therapeutics Inc. reported its condensed interim consolidated financial statements for the three and nine months ended September 30, 2024. The company faced a substantial net loss of $28.5 million during this period, which is a notable increase from $20.5 million in the previous year. Current assets significantly dropped from $36.15 million to $17.28 million, reflecting a challenging financial landscape. The overall equity also decreased markedly, raising concerns about the company's financial health as it continues its focus on developing anti-inflammatory therapies for heart disease.
Read more →CRDLCardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Cardiol Therapeutics Inc. has been included in the PRISM Emerging Biotech Index, a recognition of its impact within the biotech sector. The company focuses on anti-inflammatory and anti-fibrotic therapies for heart disease, particularly through its lead candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA for the treatment of recurrent pericarditis. Cardiol plans to initiate the Phase II/III MAVERIC-2 trial for this indication in Q4 2024. Additionally, Cardiol is advancing another therapy, CRD-38, aimed at heart failure, which indicates its commitment to developing innovative treatments in cardiac care.
Read more →CRDLCardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial in Patients with Recurrent Pericarditis
Cardiol Therapeutics plans to advance CardiolRx™ into a late-stage trial, MAVERIC-2, targeting recurrent pericarditis patients after IL-1 blocker therapy cessation. The trial, set to begin in Q4 2024, aims to assess CardiolRx™'s efficacy in preventing recurrence. This study is expected to complement the upcoming Phase III MAVERIC-3 trial, enhancing the potential market for CardiolRx™.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Advance CardiolRx into a Late-stage Trial in Patients with Recurrent Pericarditis MAVERIC-2 trial will evaluate the impact of CardiolRx following cessation of interleukin
Cardiol Therapeutics announced the advancement of CardiolRx into a late-stage trial, MAVERIC-2, to evaluate its effectiveness in patients with recurrent pericarditis after stopping IL-1 blocker therapy. The trial aims to determine CardiolRx's effect on preventing pericarditis recurrences and will begin in Q4 2024. This trial represents a strategic extension of the company's MAVERIC program, aiming ultimately for enhanced regulatory pathways and treatment options for patients. Previous studies have suggested significant improvements in pain and inflammation from CardiolRx.
Read more →CRDL▲ +5.6%on this news
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Cardiol Therapeutics Inc. has successfully completed a public offering, raising $15.5 million through the sale of 9,703,125 Class A common shares. The offering included the full exercise of an over-allotment option by Canaccord Genuity, which purchased an additional 1,265,625 shares. The funds will be used to advance the clinical development of CardiolRx and cover general expenses.
Read more →CRDL▲ +5.6%on this newsshared move
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option Oakville, ON
Cardiol Therapeutics Inc. has successfully completed a public offering, raising $13.5 million through the sale of 8,437,500 common shares at $1.60 each. Following this, Canaccord Genuity exercised the over-allotment option, purchasing an additional 1,265,625 shares for an extra $2,025,000 in gross proceeds. The funds raised will be used to support the clinical development of CardiolRx, which is aimed at treating recurrent pericarditis, along with covering general and administrative expenses.
Read more →CRDLCardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares Oakville, ON
Cardiol Therapeutics Inc. has announced the successful completion of a public offering that raised US$13.5 million by selling 8,437,500 Class A common shares at US$1.60 each. The proceeds from this offering are intended to fund the clinical development of CardiolRx, aimed at treating recurrent pericarditis, along with general administrative and working capital expenses. This development underscores Cardiol’s ongoing commitment to advancing therapies for heart disease.
Read more →CRDL▼ -6.6%on this newsshared move
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Cardiol Therapeutics Inc. has announced the pricing of its public offering of 8,437,500 Class A common shares at $1.60 each, aiming to raise $13.5 million. The funds will be used for the clinical development of CardiolRx for recurrent pericarditis and general expenses. The offering is expected to close on October 10, 2024, pending regulatory approvals.
Read more →CRDL▼ -6.6%on this newsshared move
Cardiol Therapeutics Inc. 8,437,500 Common Shares
Cardiol Therapeutics Inc. has entered into an underwriting agreement for the sale of 8,437,500 common shares, with the possibility of issuing an additional 1,265,625 shares. Underwritten by Canaccord Genuity and other firms, this initiative marks a significant step in the company's funding strategy. The offering is supported by a Canadian Base Prospectus that has received regulatory approval, allowing for the broad distribution of various securities across Canadian jurisdictions. The company aims to raise a total of up to $150 million, which will bolster its financial standing and growth potential.
Read more →CRDLCardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Cardiol Therapeutics has filed a preliminary prospectus supplement for a proposed public offering of Class A common shares. The funds raised will support the clinical development of CardiolRx for recurrent pericarditis. The offering's final terms remain uncertain and depend on market conditions and regulatory approvals.
Read more →CRDLBorden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T 416.367.6000 F 416.367.6749 blg.com
Borden Ladner Gervais LLP has provided consent for the reference of their name in various sections of a prospectus supplement related to Cardiol Therapeutics Inc.'s Class A common shares issuance. The consent pertains to the regulatory filing dated October 8, 2024, under the U.S. Registration Statement Form F-10. The firm specified that this consent does not constitute an admission of being among the persons requiring such consent under the Securities Act of 1933.
Read more →CRDLCardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx™ for Acute Myocarditis
Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, which evaluates CardiolRx™ for acute myocarditis. This milestone is crucial for understanding the drug's impact on myocardial recovery. Topline results are anticipated early next year, which may provide significant insights into treatment efficacy. The study aims to address a critical need as there are currently no FDA-approved therapies for this condition.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx for Acute Myocarditis Toronto, ON
Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial for CardiolRx, aimed at treating acute myocarditis. This milestone reflects the dedication of clinical collaborators and patients. Results are expected early next year, which will provide critical insights into the therapy's impact on myocardial recovery. Additionally, the findings are anticipated to complement data from another study in recurrent pericarditis, enhancing the overall understanding of CardiolRx's effectiveness.
Read more →CRDL▲ +5%on this news· ran to +25% by day 3
Filed by newsfilecorp.com Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 Full cli
Cardiol Therapeutics announced the completion of its MAvERIC Phase II study in recurrent pericarditis, with results set to be presented at the American Heart Association Scientific Sessions 2024. The study demonstrated that the oral administration of CardiolRx significantly reduced pericarditis pain and inflammation at the 8-week mark. Future findings will include additional endpoints, such as pericarditis recurrence and safety outcomes. The announcement positions CardiolRx as a promising non-immunosuppressive treatment for patients suffering from this chronic inflammatory condition.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2024 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated
Cardiol Therapeutics Inc. reported its unaudited condensed interim consolidated financial statements for the six months ending June 30, 2024. The company experienced a notable increase in net loss during this period, reaching CAD 15,770,505, compared to a loss of CAD 14,561,090 in the same timeframe the previous year. Total assets declined significantly from CAD 36,700,508 to CAD 26,312,660, with current assets and total equity also showing sharp decreases. The financial results indicate continued challenges for the company amidst ongoing operational costs.
Read more →CRDLCardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Cardiol Therapeutics Inc. held its annual general and special meeting on June 26, 2024, where shareholders approved all proposed resolutions. This includes the election of directors and the appointment of auditors. The company continues to advance its clinical development of therapies for heart disease, including its lead candidate CardiolRx™.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders Toronto, ON
Cardiol Therapeutics reported positive outcomes from its 2024 Annual General and Special Meeting of Shareholders. All management resolutions, including the election of directors and the appointment of auditors, received strong support from shareholders. Notable voter approval was recorded for each director nominee, demonstrating confidence in the company's leadership. Cardiol continues to advance its innovative therapies, such as CardiolRx, for heart disease, having received FDA authorization for clinical studies.
Read more →CRDL▲ +6%on this newsshared move
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Cardiol Therapeutics Inc. will host its virtual Annual General and Special Meeting on June 26, 2024, at 4:30 p.m. EDT. The meeting will be accessible via live audio webcast. The company is focused on developing anti-inflammatory therapies for heart disease and has received FDA authorization for clinical studies involving its lead drug candidate, CardiolRx™.
Read more →CRDL▲ +6%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26 th at 4:30 p.m. EDT Toronto, ON
Cardiol Therapeutics Inc. will host a virtual Annual General and Special Meeting of Shareholders on June 26, 2024. The meeting, aimed at enhancing shareholder engagement, will include details about the company's progress in developing anti-inflammatory and anti-fibrotic therapies for heart disease. Notably, CardiolRx, a drug candidate designed to treat conditions like myocarditis and pericarditis, has received FDA authorization for clinical trials, positioning the company favorably in the biopharma landscape. Additional information regarding the meeting can be found on the company’s website.
Read more →CRDL▼ -20.5%on this news
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Cardiol Therapeutics has announced positive topline results from its Phase II MAvERIC-Pilot study of CardiolRx™ for recurrent pericarditis. The study demonstrated a significant reduction in patient-reported pain and inflammation, with 80% of patients achieving normalization of CRP levels. The company plans to advance to a Phase III trial based on these encouraging results.
Read more →CRDL▼ -20.5%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis Administration of CardiolRx led to a marked reductio
Cardiol Therapeutics has announced positive topline data from its Phase II MAvERIC-Pilot study evaluating CardiolRx for recurrent pericarditis. The study reported a significant reduction in patient-reported pericarditis pain and a normalization of inflammation in 80% of patients with elevated C-reactive protein levels. Additionally, 89% of participants progressed to the extension phase of the trial. The findings suggest that CardiolRx may provide a promising non-immunosuppressive therapy option for patients suffering from this debilitating condition.
Read more →CRDLCARDIOL THERAPEUTICS INC. 602-2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual general and special meeting (the
Cardiol Therapeutics Inc. has announced its annual general and special meeting of shareholders scheduled for June 26, 2024. The meeting will be conducted online, allowing shareholders to participate, vote, and ask questions through a live webcast. Shareholders must ensure their proxies or voting instructions are submitted by the specified deadline. The corporation is utilizing notice-and-access provisions to reduce costs and promote environmental responsibility by limiting paper documentation.
Read more →CRDLCardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics announced that its Phase II ARCHER trial evaluating CardiolRx™ for acute myocarditis was presented at the World Congress on Acute Heart Failure 2024. The trial has exceeded 85% enrollment and aims to assess myocardial recovery. The design and rationale of the trial have also been accepted for publication in ESC Heart Failure journal.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
Cardiol Therapeutics Inc. reported its interim consolidated financial statements for the three months ended March 31, 2024. The company incurred a net loss of $9.18 million, an increase from a loss of $7.09 million in the same period last year. Total assets have decreased to $31.13 million, while current liabilities increased significantly. Meanwhile, the company’s cash and cash equivalents are also down to approximately $28.57 million, reflecting ongoing financial challenges.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 Scope of presentation included trial design, rationale, and blinded baseline data
Cardiol Therapeutics announced that its Phase II ARCHER trial evaluating CardiolRx for acute myocarditis was presented at the World Congress on Acute Heart Failure 2024. The trial, which is currently over 85% enrolled, aims to assess myocardial recovery and has received attention for its design and rationale, with a manuscript accepted for publication. With expected topline results from another study, MAvERIC-Pilot, in June 2024, CardiolRx positions itself as a promising candidate in treating conditions currently lacking approved therapies.
Read more →CRDLFiled by newsfilecorp.com
Cardiol Therapeutics Inc. has announced details for its upcoming Annual General and Special Meeting scheduled for June 26, 2024. The record date for notice and voting is set for May 13, 2024. The meeting will involve Class A Common shares, and the information has been filed in accordance with securities regulations via Odyssey Trust Company as the issuer's agent.
Read more →CRDL▼ -5.7%on this news
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
Cardiol Therapeutics has made significant progress in its clinical studies, completing patient enrollment in the Phase II MAvERIC-Pilot study for recurrent pericarditis and achieving over 50% enrollment in the ARCHER trial for acute myocarditis. The company received FDA Orphan Drug Designation for CardiolRx™, enhancing its market potential. Financially, Cardiol is well-positioned with sufficient funds to support operations into 2026.
Read more →CRDL▼ -5.7%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Announces Year-End 2023 Update on Operations Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx in patients with recurrent pericarditis, w
Cardiol Therapeutics has announced a significant update regarding its operational progress by year-end 2023. The company completed patient enrollment in the Phase II MAvERIC-Pilot study for CardiolRx, targeting recurrent pericarditis, and has received Orphan Drug Designation from the U.S. FDA. Additionally, over 50% enrollment has been achieved in the Phase II ARCHER trial for acute myocarditis, and results from both studies are expected in 2024. The company's financial position looks strong, funded through 2026, supporting its ongoing research and development efforts.
Read more →CRDL▼ -12%on this news
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Cardiol Therapeutics has completed patient enrollment in its Phase II MAvERIC-Pilot study, which investigates the safety and efficacy of CardiolRx™ for recurrent pericarditis. The company anticipates reporting topline results in Q2 2024, which will inform the design of a pivotal Phase III trial. CardiolRx™ has received Orphan Drug Designation from the FDA.
Read more →CRDL▼ -12%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis Topline Results Expected in Q2 2024 This is a Designated
Cardiol Therapeutics has completed patient enrollment in its Phase II MAvERIC-Pilot study, which is examining the efficacy and safety of CardiolRx for recurrent pericarditis. This pilot study involves 25 patients in the U.S., and topline results are expected to be announced in Q2 2024. The outcomes are anticipated to assist in designing a pivotal Phase III clinical trial for regulatory approval. CardiolRx has been granted Orphan Drug Designation by the FDA, highlighting its potential significance in treating this debilitating condition.
Read more →CRDL▲ +42.3%on this newsshared move
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Cardiol Therapeutics has received Orphan Drug Designation from the FDA for its lead drug candidate, CardiolRx™, aimed at treating recurrent pericarditis. This designation is based on pre-clinical and initial clinical data from the MAvERIC-Pilot Phase II study. The drug aims to alleviate debilitating symptoms associated with this rare disease, which affects a significant number of patients in the U.S.
Read more →CRDL▲ +42.3%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis Designation Based on Pre-clinical Data and Initial Clinical Data from the Compa
Cardiol Therapeutics announced that the FDA has granted Orphan Drug Designation for its lead drug candidate, CardiolRx, aimed at treating recurrent pericarditis. The designation is based on promising pre-clinical and initial Phase II clinical trial data. The MAvERIC-Pilot study focuses on assessing the safety and efficacy of CardiolRx in patients experiencing recurrent pericarditis, a condition that severely impacts quality of life. This designation presents potential marketing advantages and further incentives for clinical development.
Read more →CRDLFiled by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 - Name and Address of Company Cardiol Therapeutics Inc. 2265 Upper Middle Road East, Suite 602 Oakville, Ontario, L6H 0G5, Canada Item 2 - Date of Mat
Cardiol Therapeutics Inc. has received Orphan Drug Designation from the FDA for its leading small molecule drug candidate, CardiolRx, aimed at treating pericarditis, particularly recurrent cases. This milestone was announced as part of a material change report, highlighting the drug's ongoing Phase II clinical trials. The designation confers several advantages, including seven-year marketing exclusivity and potential for expedited regulatory review. The company's research focuses on addressing a substantial need for effective treatments for a condition affecting approximately 38,000 patients annually in the U.S.
Read more →CRDL▼ -5.4%on this news· ran to +22% by day 3
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
The article presents the 2024 Heart Disease and Stroke Statistics report from the American Heart Association, authored by Seth S. Martin and colleagues. It provides US and global data on heart disease and stroke. The report is published in the journal Circulation.
Read more →CRDL▼ -5.4%on this news· ran to +22% by day 3shared move
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Cardiol Therapeutics Inc. has announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead product, CardiolRx™, currently in clinical trials for recurrent pericarditis and acute myocarditis. This development marks a significant milestone for the company.
Read more →CRDL▼ -5.4%on this news· ran to +22% by day 3shared move
Filed by newsfilecorp.com Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market Toronto, ON
Cardiol Therapeutics has announced that it has regained compliance with all applicable listing standards of The Nasdaq Capital Market. The company received notice on January 23, 2024, confirming it meets the minimum bid price requirement necessary for continued listing. Additionally, Cardiol is in the process of developing anti-inflammatory and anti-fibrotic therapies aimed at treating heart disease, with its lead product candidate CardiolRx entering clinical studies after receiving FDA authorization.
Read more →CRDLAn Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects
The article titled 'An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects' provides a general overview of cannabidiol. However, it lacks specific details or findings, making it difficult to draw any conclusions about its implications or applications in biopharma.
Read more →CRDLCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics has surpassed 50% enrollment in its Phase II ARCHER trial, which investigates CardiolRx™ for acute myocarditis. The trial aims to assess the drug's safety and efficacy in improving myocardial recovery. Conducted across multiple international centers, it seeks to enroll 100 patients and evaluate critical cardiac function measures. This milestone highlights the commitment of clinical collaborators and patients involved in the study.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Toronto, ON
Cardiol Therapeutics has announced it has surpassed 50% enrollment in its Phase II ARCHER Trial, which investigates the safety and effects of its CardiolRx treatment on patients with acute myocarditis. This trial is designed as a multi-center, double-blind study and aims to recruit a total of 100 patients across several international locations. Myocarditis, which can lead to serious complications such as heart failure or sudden cardiac death, currently has no FDA-approved therapies. The trial's findings are expected to contribute valuable insights into the treatment of this condition.
Read more →CRDLCardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
Cardiol Therapeutics has announced that Massachusetts General Hospital will participate in its MAvERIC-Pilot study, a Phase II trial focused on recurrent pericarditis. The study aims to evaluate the safety and efficacy of CardiolRx™ and is on track to complete patient recruitment by Q1 2024. With over 50% enrollment achieved, the study is positioned to advance treatment options for this rare disease.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8 th Major Medical Centre Participating in MAvERIC-Pilot MAvERIC-Pilot
Cardiol Therapeutics has announced that Massachusetts General Hospital will participate in its MAvERIC-Pilot study, focusing on recurrent pericarditis. This Phase II study aims to assess the safety, tolerability, and efficacy of CardiolRx, with patient recruitment expected to finalize in Q1 2024. The study currently has over 50% of the targeted enrollment, contributing to research vital for improving treatment options for this rare condition. Led by prominent medical centers, this initiative represents a significant step in understanding and addressing recurrent pericarditis.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Toronto, ON
Cardiol Therapeutics announced positive results from recent studies presented at the 2023 Annual Meeting of the European Society of Cardiology. These findings highlight the efficacy of cannabidiol in inhibiting mesothelial to mesenchymal transition in an experimental model of pericarditis. The study showcases a continuation of research efforts that may indicate a broader therapeutic benefit of CardiolRx, particularly for conditions causing heart disease. The ongoing collaboration with esteemed research institutions reinforces the potential clinical applications of CardiolRx.
Read more →CRDLCannabidiol inhibits the mesothelial to mesenchymal transition in experimental pericarditis
The article discusses the potential of cannabidiol in inhibiting the mesothelial to mesenchymal transition in experimental pericarditis. However, it lacks detailed findings or specific data to support this claim. The overall content appears to be more of an announcement rather than a comprehensive study or results presentation.
Read more →CRDL▲ +12.9%on this newsshared move
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consoli
Cardiol Therapeutics Inc. has released its condensed interim consolidated financial statements for the three and nine months ending September 30, 2023. The financial results indicate a significant net loss of $20.5 million compared to $23.4 million in the same period last year. Additionally, the company's cash and cash equivalents decreased from $59.5 million to $40.5 million. Meanwhile, the deficit has widened to $134.9 million, raising concerns about financial stability moving forward.
Read more →CRDLCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Cardiol Therapeutics has surpassed 50% enrollment in its Phase II MAvERIC-Pilot study, focusing on CardiolRx™ for recurrent pericarditis. The study aims to assess safety, tolerability, and efficacy while evaluating the potential to reduce corticosteroid use. Results will inform a pivotal Phase III trial for regulatory approval. The study is being conducted at specialized centers in the U.S.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis Toronto, ON
Cardiol Therapeutics Inc. has announced that it has surpassed 50% enrollment in its Phase II MAvERIC-Pilot study aimed at evaluating CardiolRx for recurrent pericarditis. The study will assess safety and efficacy, including the potential to wean patients off corticosteroids. This milestone highlights the dedication of both clinical collaborators and patients involved in the study. Further insights from this study may pave the way for a pivotal Phase III trial which may support regulatory approval.
Read more →CRDLCardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Cardiol Therapeutics Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance, with operations unaffected. If compliance is not achieved by April 2024, Cardiol may be eligible for an additional extension or face delisting.
Read more →CRDL▼ -6.8%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Toronto, ON
Cardiol Therapeutics Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The notice does not currently impact trading or the company's operations, and Cardiol has until April 16, 2024, to regain compliance. If Cardiol cannot meet the requirement by this date, it may receive additional time or face potential delisting from Nasdaq.
Read more →CRDL▲ +14.2%on this news
Filed by newsfilecorp.com Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fracti
Cardiol Therapeutics announced positive results from a study presented at the Heart Failure Society of America Annual Scientific Meeting 2023, showing that its novel CRD-38 formulation of subcutaneously administered cannabidiol can mitigate harmful fat distribution and reduce cardiac inflammation in a heart failure model. The research suggests that cannabidiol offers multiple cardioprotective effects and has potential for aiding patient compliance due to its sustained release formulation. This study adds to the growing evidence supporting the use of cannabidiol in managing heart failure with preserved ejection fraction.
Read more →CRDL▼ -5.8%on this news· ran to +18% by day 3shared move
Cannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction
The article discusses cannabidiol as a potential treatment for heart failure with preserved ejection fraction. However, it lacks detailed information or specific findings related to the treatment's efficacy or ongoing studies. The content primarily serves as a placeholder without substantial data or insights.
Read more →CRDLA Woman’s Decade-Long Battle Living with Chronic Recurrent Pericarditis and the Impact on Her Dream of Starting a Family
Stolina Qirjazi, a 33-year-old nurse practitioner, has battled chronic recurrent pericarditis for over a decade, facing numerous health challenges and misdiagnoses. Despite the pain and limitations imposed by her condition, she remains determined to pursue her dreams, including starting a family. Stolina advocates for better awareness and treatment options for pericarditis, emphasizing the importance of community support.
Read more →CRDLCardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
Cardiol Therapeutics Inc. announced that its President and CEO, David Elsley, will present a company overview at the Cantor Fitzgerald 2023 Global Healthcare Conference. The presentation will highlight the company's focus on developing anti-inflammatory and anti-fibrotic therapies for heart disease, including their lead drug candidate, CardiolRx™, which is currently in clinical development. The event will take place on September 26, 2023, at 4:55 p.m. EDT.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference Toronto, ON
Cardiol Therapeutics Inc. announced that its President and CEO, David Elsley, will present a company overview at the Cantor Fitzgerald 2023 Global Healthcare Conference. The presentation will be broadcast live and focuses on the company's clinical development of anti-inflammatory therapies for heart disease, particularly their lead drug candidate, CardiolRx. Cardiol has received FDA approval to conduct clinical studies on recurrent pericarditis and acute myocarditis. The company aims to tackle significant healthcare challenges associated with heart disease.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx for the Treatment of Acute Myoca
Cardiol Therapeutics has announced that all collaborating clinical research centers for the ARCHER trial are now initiated and able to enroll patients. This Phase II trial aims to evaluate the safety and tolerability of CardiolRx in patients with acute myocarditis. The trial is set to randomize 100 patients globally, and full patient enrollment is expected to be completed by Q3 2024, which is six months ahead of schedule. The findings from this study could provide crucial data supporting CardiolRx as a potential treatment for this rare heart condition.
Read more →CRDLMolecular and Cellular Mechanisms of Action of Cannabidiol
The article titled 'Molecular and Cellular Mechanisms of Action of Cannabidiol' appears to be a reference to a scientific publication. However, the text does not provide specific details or insights into the content of the study, making it difficult to summarize further.
Read more →CRDLThe Invisible Burden: Understanding the Full Impact of Recurrent Pericarditis
Rachel Freeburg shares her challenging journey with recurrent pericarditis, detailing her physical, mental, and financial struggles over seven years. Initially misdiagnosed, she faced multiple health crises before finally receiving the correct diagnosis. Despite ongoing flare-ups, Rachel's determination led her to effective treatment and advocacy for insurance coverage, allowing her to regain a semblance of her active lifestyle.
Read more →CRDL▼ -6.9%on this news
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated
Cardiol Therapeutics Inc. released its condensed interim consolidated financial statements for the three and six months ended June 30, 2023. The company reported a net loss of $14.56 million for the first half of the year, which is an improvement compared to a loss of $15.44 million for the same period in 2022. Total assets decreased from approximately $62 million at the end of 2022 to $47 million by June 30, 2023, primarily due to reduced cash reserves and an increase in liabilities. The financial statements reflect ongoing struggles as the company continues its clinical development efforts in the face of substantial operational losses.
Read more →CRDLCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Cardiol Therapeutics Inc. will present an overview at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The presentation will be led by CEO David Elsley and will be broadcast live. Cardiol is focused on developing therapies for heart disease, including their lead candidate, CardiolRx™, which is in clinical development.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Present at Canaccord Genuity 43 rd Annual Growth Conference Toronto, ON
Cardiol Therapeutics Inc. will present a company overview at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The presentation will be led by President and CEO David Elsley and focuses on the company's anti-inflammatory and anti-fibrotic therapies for heart disease. CardiolRx, the company's lead drug candidate, aims to address severe heart conditions such as myocarditis and heart failure. The event highlights the company's ongoing clinical developments despite acknowledged risks in their forward-looking statements.
Read more →CRDL▼ -13.4%on this newsshared move
Filed by newsfilecorp.com Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market Oakville, ON
Cardiol Therapeutics Inc. has regained compliance with all applicable listing standards of the Nasdaq Capital Market, as confirmed by a notice received on August 7, 2023. The company is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with ongoing Phase 2 clinical programs targeting recurrent pericarditis and acute myocarditis. CEO David Elsley highlighted the importance of these programs in addressing inadequately treated conditions that affect younger populations. Cardiol continues to develop its lead candidate, CardiolRx, aimed at improving outcomes in heart disease.
Read more →CRDL▲ +12%on this news
Filed by newsfilecorp.com Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
Cardiol Therapeutics Inc. held its Annual General Meeting on June 28, 2023, where shareholders voted unanimously in favor of the proposed management resolutions. The meeting resulted in the election of several directors and the appointment of BDO Canada LLP as the company's auditors. Additionally, Cardiol is advancing clinical trials for its lead drug candidate, CardiolRx, aimed at treating serious heart conditions, highlighting its commitment to addressing heart disease through innovative therapies.
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28 th at 4:30 p.m. EDT
Cardiol Therapeutics Inc. will hold its virtual Annual General Meeting (AGM) on June 28, 2023, at 4:30 p.m. EDT. The meeting will be accessible via live audio webcast. Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies, with its lead candidate CardiolRx (cannabidiol) currently in clinical development. The company has received FDA authorization to conduct clinical trials for CardiolRx in managing heart diseases, underscoring its commitment to advancing treatments in this area.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
Cardiol Therapeutics Inc. reported its condensed interim consolidated financial statements for the three months ending March 31, 2023. The company experienced an increase in net loss compared to the previous year, with a reported loss of $7.09 million. Although interest income saw a notable rise, overall financial health appears to be weakening as indicated by a growing deficit. Current cash and cash equivalents remain high but reflect the challenges in managing operational costs.
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Year-End 2022 Update on Operations Initiated patient enrollment in a Phase II open-label clinic
Cardiol Therapeutics has announced a positive year-end update for 2022, highlighting the initiation of patient enrollment in multiple Phase II clinical trials for its lead drug candidate, CardiolRx, targeting recurrent pericarditis and acute myocarditis. The company presented data demonstrating the drug's cardioprotective effects at prominent medical conferences and has successfully obtained FDA investigational new drug authorization. With a financial reserve of $59.5 million, Cardiol is well-positioned to continue its research efforts and corporate milestones into 2026.
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cann
Cardiol Therapeutics announced positive pre-clinical study results demonstrating that cannabidiol improves cardiac function and reduces inflammation in a model of heart failure. The data, presented at the American College of Cardiology's Annual Scientific Session, suggests cannabidiol prevents hypertrophy and fibrosis in heart tissue. These findings support the ongoing ARCHER trial for CardiolRx, which is aimed at treating myocarditis. The research also offers insights into cannabidiol's impact on mitochondrial function in cardiac cells.
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx for the Treatment of Recurrent Pe
Cardiol Therapeutics has announced the enrollment of the first patient in their Phase II study evaluating CardiolRx for treating recurrent pericarditis. This multi-center pilot study aims to assess the safety and efficacy of the drug, with a total of 25 patients expected to participate. The initiative, led by renowned cardiologists, aims to provide new therapeutic options for a debilitating condition affecting many patients. The study's design includes assessment of pain reduction and improvement in clinical markers of inflammation, marking a significant step for the company in addressing this heart disease.
Read more →CRDL▲ +7.3%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx for the Treatment of Recurrent Pericarditis The
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx for the Treatment of Recurrent Pericarditis The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eli
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Oakville, ON - November 14, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company
Read more →CRDL▲ +11.3%on this news· ran to +31% by day 3shared move
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consoli
INTERIM CONSOLIDATED AND NINE MONTHS ENDED IN CANADIAN DOLLARS) Interim Consolidated Statements of Financial Position in Canadian Dollars) As at September 30, 2022 As at December 31, 2021 ASSETS Current assets Cash and cash equivalents (note 3) $ 65,532
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx in a Model of Acute Pericarditis Re
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx in a Model of Acute Pericarditis Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness an
Read more →CRDL▲ +13%on this news
Filed by newsfilecorp.com Form 51-102F3 Material Change Report Item 1 Name and Address of Company Cardiol Therapeutics Inc. (the " Corporation ") 602-2265 Upper Middle Road East Oakville, Ontario L6H 0G5 Item 2 Date of M
Material Change Report Item 1 Name and Address of Company Cardiol Therapeutics Inc. (the "Corporation") 602-2265 Upper Middle Road East Item 2 Date of Material Change Attached as Schedule "A" is a copy of the news release relating to the material change, which was disseminat
Read more →CRDL▲ +13%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases Discontinues LANCER Trial due to Lac
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases Discontinues LANCER Trial due to Lack of Eligible Patients for Recruitment Cash Runway Now Extends into 2026 Oakvill
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mecha
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis Data Presented at The Annual Scientific Meeting
Read more →CRDL▲ +11.8%on this newsshared move
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America Oa
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America Oakville, ON - September 28, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2022 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated
INTERIM CONSOLIDATED AND SIX MONTHS ENDED (EXPRESSED IN CANADIAN Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) As at June 30, 2022 As at December 31, 2021 ASSETS Current assets
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Announces First Patient Enrolled in ARCHER , a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis Multi-center, international, double-blind, randomized,
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients Oakville, ON - August 3, 2022 - C
Read more →CRDL▼ -8.7%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Reports Results of 2022 Annual General Meeting Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Reports Results of 2022 Annual General Meeting Oakville, ON - June 29, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life scie
Read more →CRDL▲ +9.8%on this newsshared move
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT Oakville, ON - June 27, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a
Read more →CRDL▲ +7.3%on this newsshared move
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors Oakville, ON - May 19, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical
Read more →CRDL▲ +12.4%on this newsshared move
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-labe
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx for Recurrent Pericarditis Third IND authorization fo
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2022 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
CARDIOL THERAPEUTICS CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2022 (EXPRESSED IN CANADIAN DOLLARS) Cardiol Therapeutics Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) As at March 31
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Year-End 2021 Update on Operations Expanded the Phase II/III LANCER clinical trial in patients
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Year-End 2021 Update on Operations Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospit
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit Oakville, ON - March 22, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),
Read more →CRDL▲ +12.8%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors Oakville, ON - March 15, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage lif
Read more →CRDLFiled by newsfilecorp.com Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial LA
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial LANCER Trial expanded to include up to 20 Additional Clinical Research Centers Oakv
Read more →CRDLTroutman Pepper Hamilton Sanders LLP 401 9th Street NW, Suite 1000 Washington, DC 20004 troutman.com
Consent of Troutman Pepper Hamilton Sanders LLP We hereby consent to the reference to our name on the face page and under the headings "Documents Filed as Part of the U.S. Registration Statement" and "Legal Matters", and to the reference to our name and use of our opinion unde
Read more →CRDL▼ -13.4%on this news· ran to -24% by day 3
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board Oakville, ON - January 19, 2022 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or t
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Statements of Financ
CARDIOL THERAPEUTICS INC. INTERIM FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED (EXPRESSED IN CANADIAN Cardiol Therapeutics Inc. Condensed Interim Statements of Financial Position (Expressed in Canadian Dollars) As at As at September 30, December 31, 2021
Read more →CRDLCARDIOL THERAPEUTICS INC. - and - COMPUTERSHARE TRUST COMPANY OF CANADA WARRANT INDENTURE November 5 , 2021 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 6 1.1 Definitions 6 1.2 Words Importing the Singular 11 1.3 Interpret
CARDIOL THERAPEUTICS INC. COMPUTERSHARE TRUST COMPANY OF CANADA ARTICLE 1 INTERPRETATION 6 1.1 Definitions 6 1.2 Words Importing the Singular 11 1.3 Interpretation not Affected by Headings 11 1.4 Day not a Business Day 11 1.5 Time of the Essence 11 1.6 Governing Law
Read more →CRDL▼ -25.2%on this newsshared move
Filed by newsfilecorp.com Form 51-102F3 Material Change Report Item 1 Name and Address of Company Cardiol Therapeutics Inc. (the " Company ") 2265 Upper Middle Road East Suite 602 Oakville, Ontario L6H 0G5 Item 2 Date of
Material Change Report Item 1 Name and Address of Company Cardiol Therapeutics Inc. (the "Company") 2265 Upper Middle Road East Item 2 Date of Material Change The news releases were disseminated through Canada Newswire and Newsfile Corp. respectively on November 3, 2021 and
Read more →CRDL▼ -25.2%on this newsshared move
Cardiol Therapeutics Inc. 16,350,000 Units
UNDERWRITING AGREEMENT Canaccord Genuity Corp. As representative of the several c/o Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 c/o Canaccord Genuity Corp. 161 Bay Street, Suite 3100 Ladies and Gentlemen: Cardiol Therapeutics Inc., a cor
Read more →CRDLUpper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Oakville, ON
2265 Upper Middle Road East, Suite Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Oakville, ON - November 2, 2021 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Compan
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx for Acute Myocarditis Oakville,
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx for Acute Myocarditis Oakville, ON - October 25, 2021 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Car
Read more →CRDL▲ +10.9%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx TM , into Brazil, Mexico, and Canada Trial designed to
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRxTM, into Brazil, Mexico, and Canada Trial designed to investigate the cardioprotective properties of CardiolRx in patients hospitalized wi
Read more →CRDL▲ +9.7%on this news
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference Oakville, ON - September 16, 2021 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants issued on
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants issued on June 4, 2020 Oakville, ON - September 10, 2021 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Compan
Read more →CRDL▲ +11.3%on this newsshared move
Filed by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Michael J. Willner to its Board of Directors Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Appoints Michael J. Willner to its Board of Directors Oakville, ON - September 7, 2021 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stag
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of Cardi
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx for Acute Myocarditis Oakville, ON - August 24, 2021 - Cardiol Therapeutics
Read more →CRDLFiled by newsfilecorp.com MATERIAL CHANGE REPORT Form 51-102F3 Item 1 - Name and Address of Company Cardiol Therapeutics Inc. (" Cardiol ") 2265 Upper Middle Road East Suite 602 Oakville, Ontario L6H 0G5 Item 2 - Date of
MATERIAL CHANGE REPORT Item 1 - Name and Address of Company Cardiol Therapeutics Inc. ("Cardiol") 2265 Upper Middle Road East Item 2 - Date of Material Change Item 3 - News Release Attached as Schedule "A" is a copy of the news release relating to the material change, which
Read more →CRDL▲ +16.1%on this news
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2021 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Statements of Financial Po
CARDIOL THERAPEUTICS INC. CONDENSED INTERIM FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED (EXPRESSED IN CANADIAN DOLLARS) Cardiol Therapeutics Inc. Condensed Interim Statements of Financial Position (Expressed in Canadian Dollars) As at June 30, 2021 As at December
Read more →CRDLFiled by newsfilecorp.com 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL" Oakville, ON
2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL" Oakville, ON - August 9, 2021 - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology com
Read more →CRDLCardiol Announces Upsize to Previously Announced Bought Deal Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES OAKVILLE, Ontario, May 06, 2021 (GLOBE NEWSWIRE) -- Cardiol Therapeutics Inc. (TSX: CRDL) (“Cardiol”
Read more →CRDLCardiol Therapeutics Announces $15 Million Bought Deal Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES. OAKVILLE, Ontario, May 05, 2021 (GLOBE NEWSWIRE) -- Cardiol Therapeutics Inc. (TSX: CRDL) (“Cardiol”
Read more →Competitive Position
How CRDL ranks across every disease it competes inCompetitive Position is a premium feature
See how CRDL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial